{"id":"W2048548454","doi":"10.1002/hep.23073","title":"A phase III study of the safety and efficacy of viramidine versus ribavirin in treatment-naïve patients with chronic hepatitis C: ViSER1 results #","year":2009,"lang":"en","type":"article","venue":"Hepatology","topic":"Hepatitis C virus research","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Valeant Pharmaceuticals International; FibroGen; Gilead Sciences; Biogen; GlaxoSmithKline; Pfizer; Bristol-Myers Squibb","keywords":"Ribavirin; Medicine; Chronic hepatitis; Internal medicine; Hepatitis C; Gastroenterology; Virology; Pharmacology; Virus","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004748329,0.001201276,0.001955439,0.0002977015,0.0003601736,0.0007574853,0.0009210487,0.001379797,0.004934102],"category_scores_gemma":[0.001839767,0.0004251737,0.001387486,0.0002583633,0.001008651,0.000790117,0.0002410709,0.00311982,0.0008912813],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006886898,"about_ca_system_score_gemma":0.001272062,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005388347,"about_ca_topic_score_gemma":0.001153844,"domain_scores_codex":[0.9983838,0.001157999,0.00006959624,0.000156625,0.0001132512,0.0001187156],"domain_scores_gemma":[0.9983104,0.0006353476,0.0003201327,0.0001136306,0.00008658189,0.0005338494],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.910356,0.02807984,0.003774076,0.0003977154,0.0008799245,0.00008683885,0.0001105493,0.0006333495,0.01172031,0.0001753954,0.002034703,0.04175135],"study_design_scores_gemma":[0.7017485,0.2866629,0.006389468,0.0000251107,0.00034425,0.0001112117,0.00001923058,0.0007256083,0.002356597,0.0001056074,0.001491756,0.00001977644],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9910572,0.002727876,0.000375846,0.0008660635,0.0001304526,0.001300189,0.001149861,0.000094683,0.002297834],"genre_scores_gemma":[0.9880124,0.00139,0.001994711,0.001462497,0.0003083067,0.001412666,0.002113854,0.00003824006,0.003267237],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004934102,"threshold_uncertainty_score":0.02511185,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02752052217696191,"score_gpt":0.3417874933959204,"score_spread":0.3142669712189585,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}